Relypsa raises $70 million for hyperkalaemia drug
This article was originally published in Scrip
Executive Summary
Relypsa, a private US biopharmaceutical company, has secured one of the highest private financings of the year to date by raising $70 million in a series B round led by new investor OrbiMed Advisors.